No. Protein Disease Site Kinase Peptide Pubmed Description 1 ESR1_HUMAN breast cancer S118 Oest_recep LHPPPQLsPFLQPHG 12118371 2 CHK2_HUMAN small-cell lung cancer T68 DUF966 SSLETVStQELYSIP 16705183 3 MYC_HUMAN acute lymphocytic leukemia; chronic myelogenous leukemia; leukemia S62 Myc_N LLPTPPLsPSRRSGL 16855632 4 MP2K1_HUMAN Alzheimer's disease S222 Pkinase LIDSMANsFVGTRSY 17064357 5 RAF1_HUMAN Alzheimer's disease S259 SQRQRSTsTPNVHMV 17064357 6 RAF1_HUMAN Alzheimer's disease S338 RPRGQRDsSYYWEIE 17064357 7 MP2K1_HUMAN Alzheimer's disease S218 Pkinase VSGQLIDsMANSFVG 17064357 8 MP2K2_HUMAN Alzheimer's disease S226 Pkinase LIDSMANsFVGTRSY 17064357 9 RAF1_HUMAN Alzheimer's disease Y341 GQRDSSYyWEIEASE 17064357 10 MP2K2_HUMAN Alzheimer's disease S222 Pkinase VSGQLIDsMANSFVG 17064357 11 RAF1_HUMAN Alzheimer's disease Y340 RGQRDSSyYWEIEAS 17064357 12 SRC_HUMAN colorectal carcinoma Y419 Pkinase_Tyr RLIEDNEyTARQGAK 17148760 colon adenocarcinoma 13 AKT1_HUMAN rhabdomyosarcoma S473 Pkinase_C RPHFPQFsYSASGTA 17848913 14 AKT1_HUMAN rhabdomyosarcoma T308 Pkinase KDGATMKtFCGTPEY 17848913 15 AKT1_HUMAN pancreatic cancer S473 Pkinase_C RPHFPQFsYSASGTA 15467756 16 AKT1_HUMAN papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma S473 Pkinase_C RPHFPQFsYSASGTA 15743786 17 CDN1B_HUMAN papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma T157 GIRKRPAtDDSSTQN 15743786 18 CDN1B_HUMAN papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma T198 PGLRRRQt_______ 15743786 19 TRAF2_HUMAN Hodgkin's lymphoma S55 zf-C3HC4 QCGHRYCsFCLASIL 19336568 constitutive phosphorylation 20 OSTP_HUMAN X-linked hypophosphatemia S117 Osteopontin DVDDTDDsHQSDESH 19775205 ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH 21 OSTP_HUMAN X-linked hypophosphatemia S126 Osteopontin QSDESHHsDESDELV 19775205 ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH 22 OSTP_HUMAN X-linked hypophosphatemia S120 Osteopontin DTDDSHQsDESHHSD 19775205 ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH 23 OSTP_HUMAN X-linked hypophosphatemia S123 Osteopontin DSHQSDEsHHSDESD 19775205 ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH 24 OSTP_HUMAN X-linked hypophosphatemia S129 Osteopontin ESHHSDEsDELVTDF 19775205 ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH 25 FOXO1_HUMAN hepatitis S256 Fork_head SPRRRAAsMDNNSKF 18316359 nonalcoholic steatohepatitis (NASH) 26 AKT1_HUMAN hepatitis S473 Pkinase_C RPHFPQFsYSASGTA 18316359 nonalcoholic steatohepatitis (NASH) 27 NPM_HUMAN Kaposi's sarcoma T199 TFIIF_alpha; Nop14 VKKSIRDtPAKNAQK 20333249 28 RYR2_HUMAN atrial fibrillation S2814 ISQTSQVsVDAAHGY 20056922 29 MDM2_HUMAN kidney cancer S166 SSRRRAIsETEENSD 19920202 nuclear localization 30 GSK3B_HUMAN sporadic inclusion-body myositis Y216 Pkinase RGEPNVSyICSRYYR 19878439 31 ESR1_HUMAN breast cancer S167 Oest_recep GGRERLAsTNDKGSM 19940156 high S167 phosphorylation in tamoxifen resistant tumors 32 GSK3B_HUMAN lymphoma S9 SGRPRTTsFAESCKP 20224723 mantle cell lymphoma, 67% of tumors showed positive S9 phosphorylation. 33 AKT1_HUMAN Parkinson's disease S473 Pkinase_C RPHFPQFsYSASGTA 19800394 34 AKT1_HUMAN breast cancer Y176 Pkinase EKATGRYyAMKILKK 20333297 35 ACK1_HUMAN breast cancer Y284 Pkinase_Tyr LPQNDDHyVMQEHRK 20333297 36 NMDE1_HUMAN HIV Encephalitis Y1325 NMDAR2_C RLLEGNFyGSLFSVP 20448061 37 ESR1_HUMAN breast cancer S106 Oest_recep PLNSVSPsPLMLLHP 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 38 ESR1_HUMAN breast cancer T311 NSLALSLtADQMVSA 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 39 ESR1_HUMAN breast cancer S167 Oest_recep GGRERLAsTNDKGSM 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 40 ESR1_HUMAN breast cancer S294 RAANLWPsPLMIKRS 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 41 SMC1A_HUMAN ataxia-telangiectasic cancer S966 SMC_N GEDSVSGsQRISSIY 12447382 42 SYUA_HUMAN synucleinopathy S129 Synuclein NEAYEMPsEEGYQDY 16847063 43 RFWD2_HUMAN ataxia-telangiectasic cancer S387 SDDSRTAsQLDEFQE 16931761 alternation: mutation of ATM protein kinase 44 STMN1_HUMAN Alzheimer's disease; schizophrenia S25 Stathmin QAFELILsPRSKESV 16925597 increased in some schizophrenic patients; decreased in patients with Alzheimer's disease 45 STMN1_HUMAN Alzheimer's disease; schizophrenia S38 Stathmin; CDC37_N SVPEFPLsPPKKKDL 16925597 increased in some schizophrenic patients; not significantly changed in patients with the Alzheimer's disease 46 PRKN2_HUMAN Parkinson's disease S131 HTDSRKDsPPAGSPA 17327227 47 HSPB1_HUMAN atherosclerosis S82 RALSRQLsSGVSEIR 15249501 48 P53_HUMAN ataxia-telangiectasia S15 P53_TAD PSVEPPLsQETFSDL 9733515 49 CHK1_HUMAN breast cancer S280 AKRPRVTsGGVSESP 17418864 50 TSC2_HUMAN tuberous sclerosis S664 Tuberin KKTSGPLsPPTGPPG 17671177 51 EGFR_HUMAN glioblastoma multiforme Y1016 DVVDADEyLIPQQGF 17575160 52 SRC_HUMAN prostate cancer Y419 Pkinase_Tyr RLIEDNEyTARQGAK 17045208 phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones. 53 ANDR_HUMAN prostate cancer Y534 MDSYSGPyGDMRLET 17045208 phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones. 54 ABL1_HUMAN leukemia Y257 Pkinase_Tyr GGQYGEVyEGVWKKY 17164333 elevated in drug resistant leukemias with T315I mutations in Abl, and is associated with increased oncogenicity 55 FOSL1_HUMAN colorectal cancer S252 ASAHRKSsSSSGDPS 17371847 In cancers where Erk1/2 is upregulated 56 FOSL1_HUMAN colorectal cancer S265 PSSDPLGsPTLLAL_ 17371847 In cancers where Erk1/2 is upregulated 57 RB_HUMAN melanoma skin cancer S807 Rb_C PGGNIYIsPLKSPYK 15502804 phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis 58 RB_HUMAN melanoma skin cancer S811 Rb_C IYISPLKsPYKISEG 15502804 phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis 59 RB_HUMAN melanoma skin cancer S795 Rb_C SPYKFPSsPLRIPGG 15502804 phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis 60 SYUA_HUMAN Parkinson's disease S129 Synuclein NEAYEMPsEEGYQDY 11813001 61 SYUA_HUMAN Parkinson's disease S129 Synuclein NEAYEMPsEEGYQDY 14579119 62 STAT3_HUMAN breast cancer Y705 DPGSAAPyLKTKFIC 18353781 63 H2AX_HUMAN testicular cancer S140 GKKATQAsQEY____ 15846060 64 YBOX1_HUMAN breast cancer S102 CSD NPRKYLRsVGDGETV 19036157 65 PTN11_HUMAN lymphoma Y584 REDSARVyENVGLMQ 17483340 Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations 66 PTN11_HUMAN lymphoma Y546 DUF1092 SKRKGHEyTNIKYSL 17483340 Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations 67 RXRA_HUMAN hepatocellular carcinoma S260 Hormone_recep NMGLNPSsPNDPVTN 11826406 68 BRCA1_HUMAN ataxia-telangiectasia S1387 EDCSGLSsQSDILTT 10866324 69 BRCA1_HUMAN ataxia-telangiectasia S1423 AVLEQHGsQPSNSYP 10866324 70 BRCA1_HUMAN ataxia-telangiectasia S1457 SEKAVLTsQKSSEYP 10866324 71 MTOR_HUMAN ovarian cancer S2448 RSRTRTDsYSAGQSV 15208673 72 AKT1_HUMAN liver cancer S473 Pkinase_C RPHFPQFsYSASGTA 15684384 73 KIT_HUMAN GIST Y721 Pkinase_Tyr CSDSTNEyMDMKPGV 15007386 74 KIT_HUMAN GIST Y703 Pkinase_Tyr DHAEAALyKNLLHSK 15007386 75 H31_HUMAN breast adenocarcinoma S11 TKQTARKsTGGKAPR 16461563 76 GSK3B_HUMAN bipolar disprder S9 SGRPRTTsFAESCKP 16806104 77 STAT1_HUMAN melanoma skin cancer Y701 DGPKGTGyIKTELIS 17785551 78 SRC_HUMAN colorectal carcinoma Y530 FTSTEPQyQPGENL_ 17974954 79 H31_HUMAN prostate cancer T12 KQTARKStGGKAPRK 18066052 80 AKT1_HUMAN melanoma skin cancer S473 Pkinase_C RPHFPQFsYSASGTA 12499277 81 AKT1_HUMAN ovarian cancer S473 Pkinase_C RPHFPQFsYSASGTA 15208673 82 GSK3B_HUMAN ovarian cancer S9 SGRPRTTsFAESCKP 15208673 83 CHK2_HUMAN bladder cancer T68 DUF966 SSLETVStQELYSIP 15361851 84 ESR1_HUMAN breast cancer S118 Oest_recep LHPPPQLsPFLQPHG 16168121 85 ESR1_HUMAN breast cancer S167 Oest_recep GGRERLAsTNDKGSM 16168121 86 GSK3B_HUMAN schizophrenia S9 SGRPRTTsFAESCKP 14745448 87 STAT3_HUMAN prostate cancer S727 NTIDLPMsPRTLDSL 18829527 88 MK03_HUMAN type 2 diabetes T202 Pkinase; YukC HDHTGFLtEYVATRW 12765939 89 IRS1_HUMAN type 2 diabetes S636 SGDYMPMsPKSVSAP 12765939 90 MK03_HUMAN type 2 diabetes Y204 Pkinase; YukC HTGFLTEyVATRWYR 12765939 91 MK01_HUMAN type 2 diabetes T185 Pkinase; YukC HDHTGFLtEYVATRW 12765939 92 MK01_HUMAN type 2 diabetes Y187 Pkinase; YukC HTGFLTEyVATRWYR 12765939 93 IBP1_HUMAN Fetal growth restriction S144 NFHLMAPsEEDHSIL 19193607 94 CREB1_HUMAN prostate cancer S129 pKID QKRREILsRRPSYRK 12900420 high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer 95 CREB1_HUMAN prostate cancer S133 pKID EILSRRPsYRKILND 12900420 high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer 96 EGFR_HUMAN non-small cell lung cancer Y1016 DVVDADEyLIPQQGF 19002495 Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. 97 EGFR_HUMAN non-small cell lung cancer Y1197 STAENAEyLRVAPQS 19002495 Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. 98 STK4_HUMAN ovarian cancer T120 Pkinase IIRLRNKtLTEDEIA 19940129 99 STK4_HUMAN ovarian cancer T183 Pkinase DTMAKRNtVIGTPFW 19940129 100 4EBP1_HUMAN psoriasis T46 eIF_4EBP GGTLFSTtPGGTRII 19663871 in lesional, but not in nonlesional, plaque-type psoriatic skin 101 4EBP1_HUMAN psoriasis T37 eIF_4EBP PPGDYSTtPGGTLFS 19663871 in lesional, but not in nonlesional, plaque-type psoriatic skin 102 SYUA_HUMAN Alzheimer's disease S129 Synuclein NEAYEMPsEEGYQDY 19889641 Lewybody disease 103 HD_HUMAN Huntington's disease S16 KAFESLKsFQQQQQQ 20064390 104 HD_HUMAN Huntington's disease S13 KLMKAFEsLKSFQQQ 20064390 105 K1C18_HUMAN hepatitis B S53 ISVSRSTsFRGGMGS 20334631 106 K1C18_HUMAN hepatitis B S34 RPVSSAAsVYAGAGG 20334631 107 CDN1B_HUMAN breast cancer Y74 CDI HKPLEGKyEWQEVEK 17254967 108 HSPB1_HUMAN breast cancer S78 PAYSRALsRQLSSGV 17697330 Only in HER-2/neu positive tumors 109 IRS1_HUMAN type 2 diabetes S1101 GCRRRHSsETFSSTP 17709744 110 KS6B1_HUMAN type 2 diabetes T412 Pkinase_C NQVFLGFtYVAPSVL 17709744 111 AKT1_HUMAN breast cancer S473 Pkinase_C RPHFPQFsYSASGTA 17545609 112 AKT2_HUMAN ovarian cancer S474 Pkinase_C RTHFPQFsYSASIRE 10822383 113 ABL1_HUMAN ataxia-telangiectasia S446 Pkinase_Tyr PYPGIDLsQVYELLE 9168116 114 STAT1_HUMAN Wilm's tumor S727 STAT1_TAZ2bind TDNLLPMsPEEFDEV 16799645 115 AKT1_HUMAN neuroblastoma T308 Pkinase KDGATMKtFCGTPEY 17234785 116 AKT1_HUMAN neuroblastoma S473 Pkinase_C RPHFPQFsYSASGTA 17234785 117 MK01_HUMAN medullary thyroid carcinoma Y187 Pkinase; YukC HTGFLTEyVATRWYR 17209045 in tumors with activated RET (S891A allele) 118 STAT3_HUMAN medullary thyroid carcinoma S727 NTIDLPMsPRTLDSL 17209045 in tumors with activated RET (S891A allele) 119 MK03_HUMAN medullary thyroid carcinoma Y204 Pkinase; YukC HTGFLTEyVATRWYR 17209045 in tumors with activated RET (S891A allele) 120 MK01_HUMAN medullary thyroid carcinoma T185 Pkinase; YukC HDHTGFLtEYVATRW 17209045 in tumors with activated RET (S891A allele) 121 MK03_HUMAN medullary thyroid carcinoma T202 Pkinase; YukC HDHTGFLtEYVATRW 17209045 in tumors with activated RET (S891A allele) 122 WWOX_HUMAN prostate cancer Y33 WW TTKDGWVyYANHTEE 15580310 123 SMAD2_HUMAN Marfan syndrome S467 SVRCSSMs_______ 15731757 124 SMAD2_HUMAN Marfan syndrome S465 SPSVRCSsMS_____ 15731757 125 GSK3B_HUMAN Alzheimer's disease S9 SGRPRTTsFAESCKP 15033922 126 NBN_HUMAN RIDDLE syndrome S343 TTPGPSLsQGVSVDE 17940005 in irradiated fibroblasts 127 SMC1A_HUMAN RIDDLE syndrome S966 SMC_N GEDSVSGsQRISSIY 17940005 in irradiated fibroblasts 128 TP53B_HUMAN RIDDLE syndrome S1778 FNKQYTEsQLRAGAG 17940005 in irradiated fibroblasts 129 CHK1_HUMAN RIDDLE syndrome S345 LVQGISFsQPTCPDH 17940005 in irradiated fibroblasts 130 AQP4_HUMAN astrocytoma S180 MIP TIFASCDsKRTDVTG 19761816 131 PAK2_HUMAN ovarian cancer S20 APPVRMSsTIFSTGG 19876919 132 IL3RB_HUMAN acute myelogenous leukemia S601 LGPPHSRsLPDILGQ 19805619 133 JUND_HUMAN ovarian cancer S100 Jun LGLLKLAsPELERLI 17001009 134 CTNB1_HUMAN ovarian cancer S33 QQQSYLDsGIHSGAT 17001009 135 IRS2_HUMAN ovarian cancer S1100 PEAARVAsPTSGVKR 17001009 136 JUN_HUMAN ovarian cancer S73 Jun VGLLKLAsPELERLI 17001009 137 JUN_HUMAN melanoma skin cancer S73 Jun VGLLKLAsPELERLI 17001009 138 JUND_HUMAN melanoma skin cancer S100 Jun LGLLKLAsPELERLI 17001009 139 CTNB1_HUMAN melanoma skin cancer S33 QQQSYLDsGIHSGAT 17001009 140 IRS2_HUMAN melanoma skin cancer S1100 PEAARVAsPTSGVKR 17001009 141 ESR1_HUMAN breast cancer S118 Oest_recep LHPPPQLsPFLQPHG 19940281 High S118 ER-alpha phosphorylation is found in some breast cancer tumors. 142 ERBB3_HUMAN ovarian cancer Y1289 CPASEQGyEEMRAFQ 20227043 143 AKT1_HUMAN ovarian cancer T308 Pkinase KDGATMKtFCGTPEY 20153512 phosphorylated in a majority of tumor specimens 144 IBP1_HUMAN Fetal growth restriction S126 GSPESPEsTEITEEE 20143870 145 IBP1_HUMAN Fetal growth restriction S194 Thyroglobulin_1 LAKAQETsGEEISKF 20143870 146 IBP1_HUMAN Fetal growth restriction S123 AEAGSPEsPESTEIT 20143870 147 ENOA_HUMAN pancreatic carcinoma S419 Enolase_C RIEEELGsKAKFAGR 20455595 presence of autoantibodies directed against phosphorylated S419 in patients with pancreatic cancer 148 STA5A_HUMAN acute lymphocytic leukemia; acute myelogenous leukemia; chronic myelogenous leukemia S780 DSLDSRLsPPAGLFT 20508164 phosphorylation of this site was not detected in bone marrow samples obtained from healthy donors 149 ESR1_HUMAN breast cancer S282 EGRGEVGsAGDMRAA 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 150 ESR1_HUMAN breast cancer S559 ESR1_C PTSRGGAsVEETDQS 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 151 ESR1_HUMAN breast cancer S104 Oest_recep FPPLNSVsPSPLMLL 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 152 ESR1_HUMAN breast cancer S118 Oest_recep LHPPPQLsPFLQPHG 20418363 S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 153 MTOR_HUMAN adrenocortical carcinoma S2448 RSRTRTDsYSAGQSV 20484036 mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis 154 RS6_HUMAN adrenocortical carcinoma S244 DUF4055 LRASTSKsESSQK__ 20484036 mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis 155 RS6_HUMAN adrenocortical carcinoma S240 DUF4055 RLSSLRAsTSKSESS 20484036 mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis 156 STAT3_HUMAN glioblastoma Y705 DPGSAAPyLKTKFIC 20455003 Y705 phosphorylation is a prognostic factor for survival (patients with higher levels had shorter overall survival than those with lower levels) 157 RS6_HUMAN tuberous sclerosis S244 DUF4055 LRASTSKsESSQK__ 17671177 158 MK01_HUMAN tuberous sclerosis T185 Pkinase; YukC HDHTGFLtEYVATRW 17671177 159 MK03_HUMAN tuberous sclerosis Y204 Pkinase; YukC HTGFLTEyVATRWYR 17671177 160 MK01_HUMAN tuberous sclerosis Y187 Pkinase; YukC HTGFLTEyVATRWYR 17671177 161 RS6_HUMAN tuberous sclerosis S240 DUF4055 RLSSLRAsTSKSESS 17671177 162 MK03_HUMAN tuberous sclerosis T202 Pkinase; YukC HDHTGFLtEYVATRW 17671177 163 KPCG_HUMAN spinocerebellar ataxia type 14 T655 Pkinase_C TRAAPALtPPDRLVL 15964845 missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674. 164 KPCG_HUMAN spinocerebellar ataxia type 14 T514 Pkinase FPGTTTRtFCGTPDY 15964845 missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674. 165 KPCG_HUMAN spinocerebellar ataxia type 14 T674 Pkinase_C QADFQGFtYVNPDFV 15964845 missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674. 166 MK03_HUMAN pulmonary emphysema T202 Pkinase; YukC HDHTGFLtEYVATRW 14764579 167 MK03_HUMAN pulmonary emphysema Y204 Pkinase; YukC HTGFLTEyVATRWYR 14764579 168 MK01_HUMAN pulmonary emphysema T185 Pkinase; YukC HDHTGFLtEYVATRW 14764579 169 MK01_HUMAN pulmonary emphysema Y187 Pkinase; YukC HTGFLTEyVATRWYR 14764579 170 FAK1_HUMAN colorectal cancer Y407 IIDEEDTyTMPSTRD 12871985 pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9). No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation. 171 FAK1_HUMAN colorectal cancer Y397 SVSETDDyAEIIDEE 12871985 pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9). No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation. 172 EGFR_HUMAN non-small cell large cell lung carcinoma; non-small cell squamous cell lung carcinoma Y869 Pkinase_Tyr LGAEEKEyHAEGGKV 16505275 173 EGFR_HUMAN hepatocellular carcinoma Y869 Pkinase_Tyr LGAEEKEyHAEGGKV 16936701 174 STAT3_HUMAN bladder cancer Y705 DPGSAAPyLKTKFIC 18939995 175 P53_HUMAN ovarian cancer S20 P53_TAD PLSQETFsDLWKLLP 20009884 In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas. 176 P53_HUMAN ovarian cancer S392 FKTEGPDsD______ 20009884 In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas. 177 FYN_HUMAN cancer, squamous cell carcinoma Y420 Pkinase_Tyr RLIEDNEyTARQGAK 19934324 178 H31_HUMAN breast cancer S29 ATKAARKsAPATGGV 19956839 mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients. 179 MTOR_HUMAN breast cancer S2481 TVPESIHsFIGDGLV 19956839 mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients. 180 H31_HUMAN breast cancer S11 TKQTARKsTGGKAPR 19956839 mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients. 181 TF65_HUMAN hepatocellular carcinoma S536 SGDEDFSsIADMDFS 20224721 fibrolamellar hepatocellular carcinoma. high levels of phosphorylation in 88% of fibrolamellar hepatocellular carcinoma sample, 10% of normal liver samples. 182 TNNT2_HUMAN LVR; MI S208 Troponin QAQTERKsGKRQTER 20418543 183 TNIK_HUMAN colorectal cancer S764 RTRVRANsKSEGSPV 20530691 184 ACK1_HUMAN prostate cancer Y284 Pkinase_Tyr LPQNDDHyVMQEHRK 20623637 correlates positively with disease progression and negatively with survival of patients 185 NFM_HUMAN Alzheimer's disease S620 AKSPVPKsPVEEKGK 20624930 186 NFM_HUMAN Alzheimer's disease S672 GKSPVSKsPVEEKAK 20624930 187 NFM_HUMAN Alzheimer's disease S685 AKSPVPKsPVEEAKS 20624930 188 NFM_HUMAN Alzheimer's disease S788 GGSEEEGsDKGAKGS 20624930 189 NFM_HUMAN Alzheimer's disease S646 GKSPVPKsPVEEKGK 20624930 190 NFM_HUMAN Alzheimer's disease S837 VTNGLDLsPADEKKG 20624930 191 NFM_HUMAN Alzheimer's disease S783 KAGGEGGsEEEGSDK 20624930 192 NFM_HUMAN Alzheimer's disease S667 PVEEKGKsPVSKSPV 20624930 193 NFM_HUMAN Alzheimer's disease S736 PEKKKAEsPVKEEAV 20624930 194 NFM_HUMAN Alzheimer's disease S659 GKSPVPKsPVEEKGK 20624930 195 NFM_HUMAN Alzheimer's disease S680 PVEEKAKsPVPKSPV 20624930 196 NFM_HUMAN Alzheimer's disease S615 EKPEKAKsPVPKSPV 20624930 197 NFM_HUMAN Alzheimer's disease S641 PVEEKGKsPVPKSPV 20624930 198 NFH_HUMAN Alzheimer's disease S801 DUF1388 PVKEEVKsPEKAKSP 20624930 199 NFH_HUMAN Alzheimer's disease S716 DUF1388; DUF1388 KSPEKAKsPVKEEAK 20624930 200 NFH_HUMAN Alzheimer's disease S648 DUF1388 PTKEEAKsPEKAKSP 20624930 201 NFH_HUMAN Alzheimer's disease S744 DUF1388 KTPEKAKsPVKEEAK 20624930 202 NFH_HUMAN Alzheimer's disease S640 DUF1388 KSPEKAKsPTKEEAK 20624930 203 NFH_HUMAN Alzheimer's disease S546 DUF1388 KSPAEVKsPEKAKSP 20624930 204 NFH_HUMAN Alzheimer's disease S710 DUF1388; DUF1388 PVKEEAKsPEKAKSP 20624930 205 NFH_HUMAN Alzheimer's disease S580 DUF1388 KSPAEVKsPEKAKSP 20624930 206 NFH_HUMAN Alzheimer's disease S702 DUF1388; DUF1388 KSPEKAKsPVKEEAK 20624930 207 NFH_HUMAN Alzheimer's disease S620 DUF1388; DUF1388 KSPAEAKsPVKEEAK 20624930 208 FSCN1_HUMAN cancer, squamous cell carcinoma S39 Fascin KVNASASsLKKKQIW 20713986 209 FYN_HUMAN breast cancer Y420 Pkinase_Tyr RLIEDNEyTARQGAK 20855525 210 EPHA2_HUMAN glioblastoma multiforme S897 RVSIRLPsTSGSEGV 19573808 high levels in grade IV astrocytomas (GBM) 211 MTOR_HUMAN ovarian epithelial carcinoma S2448 RSRTRTDsYSAGQSV 21276607 212 4EBP1_HUMAN ovarian epithelial carcinoma T37 eIF_4EBP PPGDYSTtPGGTLFS 21276607 213 KS6B1_HUMAN ovarian epithelial carcinoma T412 Pkinase_C NQVFLGFtYVAPSVL 21276607 214 4EBP1_HUMAN ovarian epithelial carcinoma T46 eIF_4EBP GGTLFSTtPGGTRII 21276607 215 TAGL2_HUMAN cholangiocellular carcinoma Y192 Calponin SQAGMTGyGMPRQIL 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 216 TRFE_HUMAN cholangiocellular carcinoma Y536 Transferrin NKEGYYGyTGAFRCL 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 217 VASP_HUMAN cholangiocellular carcinoma Y39 WH1 AFSRVQIyHNPTANS 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 218 VIME_HUMAN cholangiocellular carcinoma Y117 DUF2464; TPR_MLP1_2; DUF3584; Filament LNDRFANyIDKVRFL 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 219 YES_HUMAN cholangiocellular carcinoma Y32 VSTSVSHyGAEPTTV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 220 ALBU_HUMAN cholangiocellular carcinoma Y174 Serum_albumin ARRHPYFyAPELLFF 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 221 ANXA6_HUMAN cholangiocellular carcinoma Y95 GLMRPPAyCDAKEIK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 222 ANXA6_HUMAN cholangiocellular carcinoma Y302 Annexin TKYEKSLySMIKNDT 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 223 ANXA6_HUMAN cholangiocellular carcinoma Y609 Annexin LFFADKLyKSMKGAG 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 224 FAK1_HUMAN cholangiocellular carcinoma Y925 Focal_AT DRSNDKVyENVTGLV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 225 F16P1_HUMAN cholangiocellular carcinoma Y259 FBPase DVHRTLVyGGIFLYP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 226 F16P1_HUMAN cholangiocellular carcinoma Y265 FBPase VYGGIFLyPANKKSP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 227 FCERG_HUMAN cholangiocellular carcinoma Y65 ITAM YEKSDGVyTGLSTRN 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 228 CTNB1_HUMAN S552 QDTQRRTsMGGTQQQ 20580720 chronic ulcerative colitis (CUC), ulcerative colitis?associated dysplasia (UCD), colitis-associated cancer (CAC) 229 SP1_HUMAN SLE S59 GGQESQPsPLALLAA 21097497 230 FLI1_HUMAN scleroderma T312 Ets TNGEFKMtDPDEVAR 21321929 231 H4_HUMAN cholangiocellular carcinoma Y73 Histone VIRDAVTyTEHAKRK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 232 IRS1_HUMAN cholangiocellular carcinoma Y612 TLHTDDGyMPMSPGV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 233 IRS2_HUMAN cholangiocellular carcinoma Y675 GSCRSDDyMPMSPAS 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 234 IRS2_HUMAN cholangiocellular carcinoma Y823 CGGDSDQyVLMSSPV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 235 NCK1_HUMAN cholangiocellular carcinoma Y105 VDPGERLyDLNMPAY 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 236 PLCG1_HUMAN cholangiocellular carcinoma Y977 PI-PLC-Y IGTERACyRDMSSFP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 237 SHIP1_HUMAN cholangiocellular carcinoma Y865 GKTREKLyDFVKTER 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 238 ANDR_HUMAN prostate cancer S81 Androgen_recep QQQQQETsPRQQQQQ 21799006 xenografts 239 KPCT_HUMAN SLE T538 Pkinase LGDAKTNtFCGTPDY 21983831 activation of the KHS2-PKCT-IKK pathway controls SLE pathogenesis 240 YAP1_HUMAN lung cancer S127 PQHVRAHsSPASLQL 21060948 241 FOXA2_HUMAN hepatocellular carcinoma S111 Fork_head_N PHLSPSLsPLGGQAA 22196886 242 FOXA2_HUMAN hepatocellular carcinoma S107 Fork_head_N AGMGPHLsPSLSPLG 22196886 243 BCR_HUMAN chronic myelogenous leukemia Y177 ADAEKPFyVNVEFHH 12124177 244 STK3_HUMAN breast cancer T117 Pkinase IIRLRNKtLIEDEIA 20231902 245 STA5B_HUMAN acute lymphocytic leukemia; acute myelogenous leukemia; B cell lymphoma S193 STAT_alpha FGPLAQLsPQERLSR 22442148 constitutive phosphorylation of this site was observed 246 CTNB1_HUMAN glioblastoma Y333 NIMRTYTyEKLLWTT 22056988 247 STAT3_HUMAN hepatocellular carcinoma Y705 DPGSAAPyLKTKFIC 22153071 248 CTNB1_HUMAN prostate cancer T120 HEAT_2; RIX1 QFDAAHPtNVQRLAE 22511927 249 TP53B_HUMAN ataxia-telangiectasia S25 PCLIIEDsQPESQVL 19876065 250 FAK1_HUMAN hepatocellular carcinoma Y397 SVSETDDyAEIIDEE 20180147 Phosphorylated Y379 is overexpressed in hepaocellular carcinoma, and correlated with tumor stage, vascular invasion, and intrahepatic metastasis, 251 ATF4_HUMAN breast cancer S245 TRGSPNRsLPSPGVL 22052162 252 GFAP_HUMAN FTLD S13 Filament_head ITSAARRsYVSSGEM 20886841 253 P53_HUMAN Huntington's disease S46 AMDDLMLsPDDIEQW 22011578 254 MAP2_HUMAN Alzheimer's disease S1702 Tubulin-binding VTKKIDLsHVTSKCG 21828286 255 NFM_HUMAN Alzheimer's disease S736 PEKKKAEsPVKEEAV 21828286 256 MAP2_HUMAN Alzheimer's disease S1706 Tubulin-binding IDLSHVTsKCGSLKN 21828286 257 NFH_HUMAN Alzheimer's disease S948 DAKAKEPsKPAEKKE 21828286 258 NFM_HUMAN Alzheimer's disease S685 AKSPVPKsPVEEAKS 21828286 259 NFM_HUMAN Alzheimer's disease S33 Filament_head RVSGSPSsGFRSQSW 21828286 260 PIN1_HUMAN breast cancer S138 Rotamase QKPFEDAsFALRTGE 22566623 261 KCNH2_HUMAN ventricular tachycardia S890 RQRKRKLsFRRRTDK 22653970 phosphorylation of this site is decreased by T887H nsSNP mutation in Kv11.1 262 SYUA_HUMAN Parkinson's disease S129 Synuclein NEAYEMPsEEGYQDY 22344688 PD patients had higher S129 phosphorylation levels compared to healthy controls. Patients with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) patient, had lower S129 phosphorylation than PD patients or healthy controls. There was a weak correlation with P-S129 levels and severity of the PD. 263 TNNI3_HUMAN DCM S24 Troponin-I_N APIRRRSsNYRAYAT 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 264 TNNI3_HUMAN DCM S5 Troponin-I_N ___MADGsSDAAREP 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 265 TNNI3_HUMAN DCM S23 Troponin-I_N PAPIRRRsSNYRAYA 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 266 TNNI3_HUMAN DCM S6 Troponin-I_N __MADGSsDAAREPR 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 267 TNNI3_HUMAN DCM Y26 Troponin-I_N IRRRSSNyRAYATEP 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 268 TNNI3_HUMAN DCM T78 Troponin EKGRALStRCQPLEL 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 269 TNNI3_HUMAN DCM S42 AKKKSKIsASRKLQL 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 270 TNNI3_HUMAN DCM S77 Troponin GEKGRALsTRCQPLE 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 271 TNNI3_HUMAN DCM S44 KKSKISAsRKLQLKT 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 272 TNNI3_HUMAN DCM T181 KQVKKEDtEKENREV 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 273 TNNI3_HUMAN DCM S166 Troponin LGARAKEsLDLRAHL 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 274 TNNI3_HUMAN DCM T143 Troponin RGKFKRPtLRRVRIS 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 275 TNNI3_HUMAN DCM S199 RKNIDALsGMEGRKK 22972900 similar effect has been observed in ISHD (failing ischemic hearts) 276 AKT1_HUMAN urethral cancer; brain cancer; colorectal cancer S473 Pkinase_C RPHFPQFsYSASGTA 22975685 277 ELK1_HUMAN colorectal carcinoma T417 ISVDGLStPVVLSPG 23114923 278 SP1_HUMAN lung cancer T739 SEGSGTAtPSALITT 22266860 279 LIPS_HUMAN obesity, hyperphagic S853 IAEPMRRsVSEAALA 18398140 280 LIPS_HUMAN obesity, hyperphagic S950 Abhydrolase_3 EGFHPRRsSQGATQM 18398140 281 LIPS_HUMAN obesity, hyperphagic S855 EPMRRSVsEAALAQP 18398140 282 IF4E_HUMAN psoriasis S209 DTATKSGsTTKNRFV 19663871 in lesional, but not in nonlesional, plaque-type psoriatic skin 283 GSK3B_HUMAN type 2 diabetes S9 SGRPRTTsFAESCKP 15033922 284 EF1A1_HUMAN breast ductal carcinoma S300 GTP_EFTU_D2 EMHHEALsEALPGDN 20832312 285 P53_HUMAN Down syndrome S15 P53_TAD PSVEPPLsQETFSDL 20696760 286 TBCD4_HUMAN type 2 diabetes S588 RMRGRLGsVDSFERS 20938636 287 TBCD4_HUMAN type 2 diabetes S318 PID EFRSRCSsVTGVQRR 20938636 288 TBCD4_HUMAN type 2 diabetes S751 EGRKRTSsTCSNESL 20938636 289 AKT1_HUMAN type 2 diabetes T308 Pkinase KDGATMKtFCGTPEY 20938636 insulin-stimulated phosphorylation 290 AKT1_HUMAN thymic carcinoma S473 Pkinase_C RPHFPQFsYSASGTA 20597130 AKT473 phosphorylation negative patients showed a trend toward better survival and progression than AKT4723 positive patients. 291 SYUA_HUMAN Parkinson's disease S129 Synuclein NEAYEMPsEEGYQDY 21865317 292 CALD1_HUMAN prostate cancer S789 QSVDKVTsPTKV___ 22197205 293 ACTN4_HUMAN cholangiocellular carcinoma Y265 CH MTYVSSFyHAFSGAQ 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 294 ANXA2_HUMAN cholangiocellular carcinoma Y188 YodA EDGSVIDyELIDQDA 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 295 APLP2_HUMAN cholangiocellular carcinoma Y750 APP_amyloid NKMQNHGyENPTYKY 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 296 CDK2_HUMAN cholangiocellular carcinoma Y15 Pkinase EKIGEGTyGVVYKAR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 297 FGR_HUMAN cholangiocellular carcinoma Y208 SH2 RKLDMGGyYITTRVQ 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 298 MUC1_HUMAN cholangiocellular carcinoma Y1212 IncA PMSEYPTyHTHGRYV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 299 VIME_HUMAN cholangiocellular carcinoma Y38 Filament_head; DUF2464 VTTSTRTySLGSALR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 300 DDR1_HUMAN cholangiocellular carcinoma Y796 Pkinase_Tyr RNLYAGDyYRVQGRA 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 301 FGR_HUMAN cholangiocellular carcinoma Y412 Pkinase_Tyr RLIKDDEyNPCQGSK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 302 MUC1_HUMAN cholangiocellular carcinoma Y1209 IncA TYHPMSEyPTYHTHG 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 303 MK13_HUMAN cholangiocellular carcinoma Y182 Pkinase ADAEMTGyVVTRWYR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 304 KSYK_HUMAN cholangiocellular carcinoma Y352 TEVYESPyADPEEIR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 305 AKT1_HUMAN melanoma skin cancer S473 Pkinase_C RPHFPQFsYSASGTA 19996208 306 AKT1_HUMAN melanoma skin cancer T308 Pkinase KDGATMKtFCGTPEY 19996208 307 GSK3A_HUMAN melanoma skin cancer S21 SGRARTSsFAEPGGG 19996208 308 GSK3B_HUMAN melanoma skin cancer S9 SGRPRTTsFAESCKP 19996208 309 ESR1_HUMAN breast cancer Y52 Oest_recep DSSKPAVyNYPEGAA 20101225 310 ESR1_HUMAN breast cancer Y219 zf-C4 SIQGHNDyMCPATNQ 20101225 311 GSK3B_HUMAN Alzheimer's disease S9 SGRPRTTsFAESCKP 22278060 312 HDAC5_HUMAN cardiomyopathy S279 KVAERRSsPLLRRKD 20716686 inhibits cardiomyocyte hypertrophy 313 AAPK1_HUMAN type 2 diabetes T183 Pkinase SDGEFLRtSCGSPNY 20938636 314 CASP8_HUMAN breast ductal carcinoma S387 Peptidase_C14 YLEMDLSsPQTRYIP 20937773 315 ECT2_HUMAN non-small cell lung cancer T359 YLYEKANtPELKKSV 21189248 316 RIPK2_HUMAN Crohn disease Y474 CARD DLIMKEDyELVSTKP 21123652 317 SYUA_HUMAN Parkinson's disease S129 Synuclein NEAYEMPsEEGYQDY 21849493 318 PTEN_HUMAN PEL S380 EPDHYRYsDTTDSDP 21819957 319 PTEN_HUMAN Kaposi's sarcoma S380 EPDHYRYsDTTDSDP 21819957 320 RS6_HUMAN Kaposi's sarcoma S235 DUF4055 IAKRRRLsSLRASTS 21819957 321 AKT1_HUMAN Kaposi's sarcoma T308 Pkinase KDGATMKtFCGTPEY 21819957 322 RS6_HUMAN Kaposi's sarcoma S236 DUF4055 AKRRRLSsLRASTSK 21819957 323 BAD_HUMAN ovarian cancer S75 Bcl-2_BAD EIRSRHSsYPAGTED 21849418 Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival. 324 BAD_HUMAN ovarian cancer S99 Bcl-2_BAD; Bclx_interact PFRGRSRsAPPNLWA 21849418 Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival. 325 BAD_HUMAN ovarian cancer S118 Bcl-2_BAD; Bclx_interact GRELRRMsDEFVDSF 21849418 Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival. 326 P53_HUMAN hepatocellular carcinoma S392 FKTEGPDsD______ 21455220 327 IF4E_HUMAN prostate cancer S209 DTATKSGsTTKNRFV 20679199 hormone refractory human prostate cancer 328 AKT1_HUMAN type 2 diabetes T308 Pkinase KDGATMKtFCGTPEY 15919790 329 RAF1_HUMAN S259 SQRQRSTsTPNVHMV 20679480 Noonan syndrome mutations lead to dephosphorylation of S259 and impaired 14-3-3 binding. 330 STAT3_HUMAN fibrosarcoma of soft tissue Y705 DPGSAAPyLKTKFIC 21575192 Y705 phosphorylation was significantly associated with tumor grade. 331 ALBU_HUMAN cholangiocellular carcinoma Y108 Serum_albumin VATLRETyGEMADCC 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 332 ANX11_HUMAN cholangiocellular carcinoma Y482 Annexin RMYGKSLyHDISGDT 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 333 ANXA2_HUMAN cholangiocellular carcinoma Y199 YodA; Annexin DQDARDLyDAGVKRK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 334 ANXA2_HUMAN cholangiocellular carcinoma Y238 YodA; Annexin RYKSYSPyDMLESIR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 335 PTK6_HUMAN cholangiocellular carcinoma Y114 SH2 SEKPSADyVLSVRDT 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 336 PTK6_HUMAN cholangiocellular carcinoma Y447 RLSSFTSyENPT___ 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 337 CDK1_HUMAN cholangiocellular carcinoma Y15 Pkinase EKIGEGTyGVVYKGR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 338 CDK3_HUMAN cholangiocellular carcinoma Y15 Pkinase EKIGEGTyGVVYKAK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 339 CTND1_HUMAN cholangiocellular carcinoma Y228 YPGGSDNyGSLSRVT 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 340 DDR2_HUMAN cholangiocellular carcinoma Y740 Pkinase_Tyr RNLYSGDyYRIQGRA 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 341 FLNA_HUMAN cholangiocellular carcinoma Y2388 Filamin TEIDQDKyAVRFIPR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 342 LSR_HUMAN cholangiocellular carcinoma Y323 TSGVPSIyAPSTYAH 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 343 FRK_HUMAN cholangiocellular carcinoma Y387 Pkinase_Tyr KVDNEDIyESRHEIK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is less than 0.5; total number of phosphopeptides is >=5 344 ESR2_HUMAN breast cancer S105 ERbeta_N; Oest_recep LYAEPQKsPWCEARS 20696772 associated with improved disease-free and overall survival 345 STAT3_HUMAN colorectal carcinoma Y705 DPGSAAPyLKTKFIC 21166956 346 TWST1_HUMAN breast cancer S68 GGGDEPGsPAQGKRG 21502402 347 GSK3B_HUMAN pancreatic cancer S9 SGRPRTTsFAESCKP 21474066 phosphorylation associated with poor overall survival 348 AKT1_HUMAN pancreatic cancer S473 Pkinase_C RPHFPQFsYSASGTA 21474066 phosphorylation associated with poor overall survival 349 MTOR_HUMAN pancreatic cancer S2448 RSRTRTDsYSAGQSV 21474066 phosphorylation associated with poor overall survival 350 SYUA_HUMAN Parkinson's disease S129 Synuclein NEAYEMPsEEGYQDY 21562258 351 CLD2_HUMAN cholangiocellular carcinoma Y195 CD20; Trp_oprn_chp QRNRSNYyDAYQAQP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 352 CLD2_HUMAN cholangiocellular carcinoma Y198 CD20; Trp_oprn_chp RSNYYDAyQAQPLAT 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 353 CLH1_HUMAN cholangiocellular carcinoma Y899 Clathrin RFLRENPyYDSRVVG 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 354 SRC8_HUMAN cholangiocellular carcinoma Y446 GTEPEPVySMEAADY 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 355 CTND1_HUMAN cholangiocellular carcinoma Y257 APSRQDVyGPQPQVR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 356 DDR1_HUMAN cholangiocellular carcinoma Y513 LLLSNPAyRLLLATY 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 357 DDR1_HUMAN cholangiocellular carcinoma Y792 Pkinase_Tyr FGMSRNLyAGDYYRV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 358 DDR1_HUMAN cholangiocellular carcinoma Y797 Pkinase_Tyr NLYAGDYyRVQGRAV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 359 DDX3X_HUMAN cholangiocellular carcinoma Y104 DDRGRSDyDGIGSRG 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 360 IF4A3_HUMAN cholangiocellular carcinoma Y54 EDLLRGIyAYGFEKP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 361 DESP_HUMAN cholangiocellular carcinoma Y56 TDQNSDGyCQTGTMS 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 362 EF1A1_HUMAN cholangiocellular carcinoma Y29 GTP_EFTU TTTGHLIyKCGGIDK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 363 IF4A2_HUMAN cholangiocellular carcinoma Y49 ESLLRGIyAYGFEKP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 364 EPHA2_HUMAN cholangiocellular carcinoma Y594 TYVDPHTyEDPNQAV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 365 EPHA2_HUMAN cholangiocellular carcinoma Y772 Pkinase_Tyr EDDPEATyTTSGGKI 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 366 JAM1_HUMAN cholangiocellular carcinoma Y280 TSSKKVIySQPSARS 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 367 FLNA_HUMAN cholangiocellular carcinoma Y1604 Filamin QDNHDGTyTVAYVPD 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 368 PRKN2_HUMAN Parkinson's disease Y143 SPAGRSIyNSFYVYC 20823226 369 ITB1_HUMAN cholangiocellular carcinoma Y783 Integrin_b_cyt DTGENPIyKSAVTTV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 370 ITB1_HUMAN cholangiocellular carcinoma Y795 Integrin_b_cyt TTVVNPKyEGK____ 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 371 ITB4_HUMAN cholangiocellular carcinoma Y1207 fn3 GAQGEGPySSLVSCR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 372 K1C18_HUMAN cholangiocellular carcinoma Y13 RSTFSTNyRSLGSVQ 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 373 K2C8_HUMAN cholangiocellular carcinoma Y204 Filament; Myosin_tail_1; DUF1664; Fib_alpha; TPR_MLP1_2; ATG16 KKDVDEAyMNKVELE 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 374 K2C8_HUMAN cholangiocellular carcinoma Y267 Filament; Myosin_tail_1; Fib_alpha; E2R135; Spc7; Myosin_tail_1 IAEVKAQyEDIANRS 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 375 K2C8_HUMAN cholangiocellular carcinoma Y282 Filament; Fib_alpha; E2R135; Spc7; Myosin_tail_1 RAEAESMyQIKYEEL 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 376 LSR_HUMAN cholangiocellular carcinoma Y535 SRSRDDLyDQDDSRD 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 377 LSR_HUMAN cholangiocellular carcinoma Y551 PRSRDPHyDDFRSRE 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 378 TRFL_HUMAN cholangiocellular carcinoma Y547 Transferrin SNERYYGyTGAFRCL 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 379 MUC1_HUMAN cholangiocellular carcinoma Y1203 IncA IFPARDTyHPMSEYP 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 380 MUC1_HUMAN cholangiocellular carcinoma Y1229 SSTDRSPyEKVSAGN 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 381 MYH9_HUMAN cholangiocellular carcinoma Y754 Myosin_head LELDSNLyRIGQSKV 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 382 MYH9_HUMAN cholangiocellular carcinoma Y1408 Myosin_tail_1; Reo_sigmaC; CALCOCO1 HEEKVAAyDKLEKTK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 383 MK12_HUMAN cholangiocellular carcinoma Y185 Pkinase ADSEMTGyVVTRWYR 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 384 PGFRA_HUMAN cholangiocellular carcinoma Y762 Pkinase_Tyr SDIQRSLyDRPASYK 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 385 KPCD_HUMAN cholangiocellular carcinoma Y313 SSEPVGIyQGFEKKT 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 386 PLEC_HUMAN cholangiocellular carcinoma Y3362 RARQEELySELQARE 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 387 PTN11_HUMAN cholangiocellular carcinoma Y62 SH2 KIQNTGDyYDLYGGE 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5 388 SRC_HUMAN cholangiocellular carcinoma Y530 FTSTEPQyQPGENL_ 21253578 ratio of the number of phosphopeptides observed in disease tissue vs. surrounding tissue is greater than 2; total number of phosphopeptides is >=5